ImmunityBio (NASDAQ: IBRX) adds $75M non-dilutive cash and converts $25M debt

Rhea-AI Filing Summary

ImmunityBio, Inc. amended its Revenue Interest Purchase Agreement, raising $75.0 million in additional non-dilutive financing in exchange for higher royalty-style payments on net sales in a defined global territory. The tiered revenue interest rate increased to 5.625%–12.50% of net sales, with future rate adjustments tied to whether cumulative payments reach $375.0 million by the end of 2029 and an overall cap at 195% of cumulative purchaser payments. Simultaneously, Nant Capital, an affiliate of the Executive Chairman, converted $25.0 million of a convertible promissory note into 4,606,596 common shares, reducing the note’s principal to $480.0 million. A related press release highlights that total committed capital under the royalty agreement has risen to $375 million and underscores recent global approvals for ANKTIVA®.

Positive

• $75.0 million in additional non-dilutive royalty financing increases liquidity to support commercial scaling and pipeline investment without immediate equity dilution.
• Conversion of $25.0 million of convertible note principal into 4,606,596 shares by Nant Capital reduces debt to $480.0 million and indicates insider confidence.
• Total committed capital under the royalty agreement rises to $375 million, providing a sizable dedicated funding source for ImmunityBio’s strategy.
• ANKTIVA® is now approved or authorized across regulatory jurisdictions representing approximately 34 countries, achieved in under two years from initial U.S. approval, demonstrating rapid global adoption.

Negative

• None.

Insights

Biotech credit & capital structure analyst

$75M royalty financing and $25M debt-to-equity conversion strengthen liquidity but raise future revenue sharing.

ImmunityBio secured an extra $75.0 million under its royalty-style Revenue Interest Purchase Agreement, lifting total committed capital to $375 million. In return, it increased the tiered revenue interest rate to 5.625%–12.50% of net sales in the covered territory, with payments owed until investors receive 195% of cumulative purchaser payments.

The structure includes a 2029 test: if aggregate revenue interest payments reach $375.0 million, the rate falls to a single 2.8125%; otherwise, it resets to a higher single rate designed to deliver that amount over the test period. This ties the company’s future cash outflows directly to commercial performance.

Concurrently, Nant Capital converted $25.0 million of a convertible promissory note into 4,606,596 shares, trimming the note’s principal to $480.0 million. That modestly de-levers the balance sheet and signals insider alignment, while the royalty financing provides near-term cash to support ANKTIVA® commercialization and global expansion highlighted in the press release.

8-K Event Classification

5 items: 1.01, 2.03, 7.01, 8.01, 9.01

5 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement Financial

The company incurred a new significant debt or off-balance-sheet obligation.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Additional royalty financing: $75.0 million Total committed RIPA capital: $375 million Tiered revenue interest rate: 5.625%–12.50% +5 more

8 metrics

Additional royalty financing $75.0 million Third Payment under amended Revenue Interest Purchase Agreement

Total committed RIPA capital $375 million Total capital committed under royalty agreement after amendment

Tiered revenue interest rate 5.625%–12.50% Percentage of net sales in the covered territory after amendment

Cumulative purchaser payments test $375.0 million Threshold by last business day of 2029 for rate reset

Royalty cap 195% of cumulative purchaser payments Aggregate revenue interest payment cap before termination

Debt converted to equity $25.0 million Principal of convertible note exchanged for common stock by Nant Capital

Shares issued on conversion 4,606,596 shares Common stock issued to Nant Capital in partial note conversion

Remaining note principal $480.0 million Outstanding principal on the Convertible Promissory Note after conversion

Key Terms

Revenue Interest Purchase Agreement, non-dilutive financing, royalty payback rate, convertible Promissory Note, +2 more

6 terms

Revenue Interest Purchase Agreement financial

"entered into a Second Amendment to Revenue Interest Purchase Agreement (the “Amendment”)"

A revenue interest purchase agreement is a contract where a business sells a portion of its future sales or product revenue to an investor in exchange for an upfront payment. For investors, it matters because the buyer gains a predictable cash stream tied to sales rather than ownership, and for the company it provides immediate funding but reduces the amount of future revenue available to owners — like selling future tolls from a road to raise cash today.

non-dilutive financing financial

"secured $75 million in non-dilutive financing under its existing Royalty Interest Purchase Agreement"

Financing that provides cash to a company without issuing new shares or reducing existing shareholders’ ownership stakes, such as grants, loans, or royalty and partnership deals. It matters to investors because it preserves each shareholder’s percentage of the company and potential future earnings—think of it as getting money by borrowing or winning a prize rather than selling extra slices of the ownership pie—though it can shift risks toward debt or contractual obligations.

royalty payback rate financial

"The amended agreement maintains existing terms, with a modest increase in the royalty payback rate"

convertible Promissory Note financial

"under that certain convertible Second Amended and Restated Promissory Note, dated December 10, 2024"

A convertible promissory note is a loan a company takes now that can later be turned into shares instead of being repaid in cash. Think of it as lending money with the option to accept ownership in the business down the road; that matters to investors because it affects who gets paid first, how much ownership existing shareholders keep, and the company’s future valuation and cash needs. Terms such as conversion price, interest and maturity determine the financial impact.

BCG-unresponsive non-muscle invasive bladder cancer medical

"for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS)"

A form of bladder cancer confined to the inner lining of the bladder that has not spread into the muscle, and that has failed to respond to or has returned after standard treatment with BCG immunotherapy. It matters to investors because these patients represent a clear, often underserved market for new medicines and devices; success in this group can unlock regulatory approvals, premium pricing, and significant commercial opportunity—similar to finding a new key when the old one no longer opens an important door.

IL-15 receptor superagonist medical

"ANKTIVA is a first-in-class IL-15 receptor superagonist IgG1 fusion complex"

An IL-15 receptor superagonist is a lab-modified form of the immune signaling protein interleukin‑15 that strongly stimulates the receptor pathway controlling certain immune cells that attack tumors and infected cells. For investors, these molecules matter because they aim to boost the effectiveness of immunotherapies—think of turning up the volume on the body’s cancer-fighting cells—and therefore offer the potential for higher therapeutic impact but also carry development and safety risks.

Understanding 8-K Material Events →

false 0001326110 0001326110 2026-03-30 2026-03-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 30, 2026

ImmunityBio, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-37507		43-1979754
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

3530 John Hopkins Court

San Diego, California 92121

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (844) 696-5235

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		IBRX		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

Amendment to Revenue Interest Purchase Agreement

On March 30, 2026, ImmunityBio, Inc. (the “Company”) entered into a Second Amendment to Revenue Interest Purchase Agreement (the “Amendment”) by and among the Company, the guarantors party thereto, the purchasers party thereto (the “Purchasers”) and Infinity SA LLC, as collateral agent and administrative agent for the Purchasers (the “Agent”), which amends that certain Revenue Interest Purchase Agreement dated as of December 29, 2023, by and among the Company, the Purchasers and the Agent (as amended, modified and supplemented prior to the date of the Amendment, the “RIPA”). Pursuant to the Amendment, the Purchasers acquired additional revenue interests (“Revenue Interests”) from the Company for a gross purchase price of $75.0 million (the “Third Payment”) paid at the closing of the Amendment.

As a result of the purchase of the additional Revenue Interests from the Company, the Purchasers have a right to receive quarterly payments (“Revenue Interest Payments”) from the Company based on net sales of the Company’s products during such quarter, which payment amount, pursuant to the Amendment, was increased to a tiered range of 5.625% to 12.50% (before funding of the Third Payment, 4.5% to 10.0%) of the Company’s net sales across the entire world, excluding the People’s Republic of China, Hong Kong and any territories controlled by the People’s Republic of China (the “Covered Territory”); provided that (a) if the aggregate Revenue Interest Payments made to the Purchasers as of the last business day of 2029 (the “Test Date”) equal or exceed $375.0 million (the “Cumulative Purchaser Payments”) as of the Test Date, the tiered revenue interest rate will be decreased to a single rate of 2.8125% (before the funding of the Third Payment, 2.25%) of the Company’s net sales in the Covered Territory, and (b) if the aggregate Revenue Interest Payments made to the Purchasers as of the Test Date do not equal or exceed the aggregate amount of Cumulative Purchaser Payments as of the Test Date, then as of and following the Test Date, the initially tiered revenue interest rate will be increased for all subsequent calendar years to a single defined rate that, had such increased rate applied to the applicable tiered rate during the period from the Closing Date through and including the Test Date, it would have resulted in the Purchasers having received aggregate Revenue Interest Payments (excluding certain payments detailed in the RIPA) in an amount equal to the Cumulative Purchaser Payments as of the Test Date.

The Purchasers’ rights to receive the Revenue Interest Payments shall terminate on the date on which the Purchasers have received Revenue Interest Payments in an aggregate amount equal to 195% of the then Cumulative Purchaser Payments, unless, in certain situations detailed in the RIPA, the RIPA is terminated prior to such date.

The proceeds of the Third Payment will be used for general corporate purposes, including payment of transaction expenses incurred in connection with the Amendment and related RIPA documentation.

The Company’s obligations under the RIPA, as amended by the Amendment, are guaranteed by certain of its subsidiaries. To secure the Company’s obligations under the RIPA, amended by the Amendment, and the subsidiary guarantors’ obligations under the guarantees, each of the Company and the subsidiary guarantors has granted a security interest in substantially all its assets, subject to certain exceptions and limitations.

The foregoing is only a brief description of the material terms of the Amendment, does not purport to be a complete description of the rights and obligations of the parties thereunder, and is qualified in its entirety by reference to the Amendment that is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

To the extent relevant, the information set forth in Item 1.01 above is incorporated by reference into this Item 2.03.

Item 7.01 Regulation FD Disclosure.

On March 31, 2026, the Company issued a press release announcing the Amendment and the Partial Note Conversion described in Item 8.01 below. The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Item 8.01 Other Events.

Also on March 30, 2026, simultaneous with the execution of the Amendment, Nant Capital, LLC, an entity affiliated with Dr. Patrick Soon-Shiong, the Company’s Executive Chairman and Global Chief Scientific and Medical Officer, converted $25.0 million of the principal amount outstanding under that certain convertible Second Amended and Restated Promissory Note, dated December 10, 2024, as amended (the “Convertible Promissory Note”), into 4,606,596 shares of Common Stock of the Company pursuant to the terms of the Convertible Promissory Note (the “Partial Note Conversion”). Following the Partial Note Conversion, the principal amount outstanding under the Convertible Promissory Note is $480.0 million.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description of Exhibit
10.1*		Second Amendment to Revenue Interest Purchase Agreement, dated as of March 30, 2026 by and among the Company, guarantors party thereto, the purchasers party thereto, and Infinity SA LLC, as collateral agent and administrative agent for the Purchasers.
99.1**		Press Release dated March 31, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

* Filed herewith.

** Furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						IMMUNITYBIO, INC.
						Registrant
Date: March 31, 2026				By:		/s/ David C. Sachs
						David C. Sachs
						Chief Financial Officer

Exhibit 99.1

NEWS RELEASE

ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline

• ImmunityBio to receive $75 million in non-dilutive funding under existing Revenue Interest Purchase Agreement (RIPA) with Oberland Capital, bringing total committed capital to $375 million

• Simultaneously conversion of $25 million of the outstanding promissory note held by Nant Capital, an entity affiliated with Executive Chairman bolstering ImmunityBio’s balance sheet with reduction in the debt

• Proceeds strengthen ImmunityBio’s balance sheet and support global expansion following recent approvals, while advancing company’s broader immunotherapy pipeline

CULVER CITY, Calif., March 31, 2026 — ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated, commercial-stage immunotherapy company, today announced it has secured $75 million in non-dilutive financing under its existing Royalty Interest Purchase Agreement (RIPA) with Oberland Capital, increasing the total committed capital under the Agreement to $375 million. The amended agreement maintains existing terms, with a modest increase in the royalty payback rate while maintaining the royalty cap.

“This additional non-dilutive financing gives us the capacity to continue scaling our commercial efforts and expanding globally following recent ANKTIVA^® approvals, while positioning us to take full advantage of the growth opportunities ahead,” said Richard Adcock, President and CEO of ImmunityBio. “The strengthening of the company’s balance sheet through non-dilutive financing from Oberland, combined with the Founder’s reduction of debt, supports our global expansion following recent approvals and the advancement of our immunotherapy pipeline.”

Simultaneous with the closing of the amendment to the RIPA, Nant Capital, LLC, an entity affiliated with our Executive Chairman, converted $25 million principal amount with the issuance of 4.6 million shares of the company’s common stock to Nant Capital, LLC and the reduction of debt under the $505 million December 2024 Promissory Note.

“The non-dilutive financing from Oberland and the conversion of debt to equity by Nant Capital, reflect strong confidence in ImmunityBio’s strategy and growth potential as a leading immunotherapy company paving the way for next-generation immunotherapy treatments,” said Patrick Soon-Shiong, M.D., Founder, Executive Chairman and Global Chief Medical and Scientific Officer of ImmunityBio.

Global Regulatory Approvals

ANKTIVA^® in combination with BCG for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS), with or without papillary tumors, is now approved or authorized across five regulatory jurisdictions, representing approximately 34 countries:

• United States: U.S. Food and Drug Administration (FDA) approval (April 2024)

• United Kingdom: Medicines and Healthcare products Regulatory Agency (MHRA) authorization (July 2025)

• Kingdom of Saudi Arabia: Saudi Food and Drug Authority (SFDA) accelerated approval for BCG-unresponsive NMIBC CIS (January 2026) and conditional accelerated approval for metastatic non-small cell lung cancer (NSCLC) in combination with checkpoint inhibitors (January 2026), the first jurisdiction globally to authorize ANKTIVA for lung cancer

• European Union: European Commission conditional marketing authorization covering all 27 EU member states plus Iceland, Norway, and Liechtenstein (February 2026)

• Macau Special Administrative Region (SAR): Pharmaceutical Administration Bureau authorization (March 2026)

This global regulatory footprint of 34 countries was established in under two years from initial U.S. FDA approval in 2024, reflecting rapid international expansion.

About ANKTIVA^® (nogapendekin alfa inbakicept-pmln)

The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved in killing cancer cells. By activating NK cells, ANKTIVA^® overcomes the tumor escape phase of clones resistant to T cells and restores memory T cell activity with resultant prolonged duration of complete response. ANKTIVA is a first-in-class IL-15 receptor superagonist IgG1 fusion complex, consisting of an IL-15 mutant (IL-15N72D) fused with an IL-15 receptor alpha, which binds with high affinity to IL-15 receptors on NK, CD4+, and CD8+ T cells. This fusion complex of ANKTIVA^® mimics the natural biological properties of the dendritic cell membrane-bound IL-15 receptor alpha driving the activation and proliferation of NK cells with the generation of memory killer T cells that have retained immune memory against these tumor clones.

About ImmunityBio

ImmunityBio, Inc. is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases. Our approach harnesses both the adaptive and innate immune systems with the goal of restoring immune function and generating lasting immunological memory in patients. At the core of our strategy is the Cancer BioShield^™ platform, which is designed to stimulate critical lymphocytes, including natural killer (NK) cells, cytotoxic T cells, and memory T cells via our proprietary IL-15 receptor superagonist, ANKTIVA^® (nogapendekin alfa inbakicept). Our Cancer BioShield platform is anchored by this antibody-cytokine fusion protein and is complemented by a portfolio that includes adenovirus-vectored vaccines, allogeneic (off-the-shelf) and autologous NK-cell therapies, and additional immunomodulators intended to promote immunogenic cell death and support durable immune responses while potentially reducing reliance on high-dose chemo-radiation therapy. For more information, visit ImmunityBio.com and connect with us on X (Twitter), Facebook, LinkedIn, and Instagram.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the clinical development, therapeutic potential, safety, efficacy, and regulatory pathway of ANKTIVA; the anticipated clinical benefits of ANKTIVA plus BCG in patients with BCG-naïve non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS); the potential for ANKTIVA plus BCG to improve durability of complete response compared to BCG alone; the anticipated impact of the funding under the RIPA to support continued scaling of ImmunityBio’s commercial efforts and global expansion following recent approvals, while advancing the Company’s broader immunotherapy pipeline; and payments to be made under the RIPA, as amended.

These forward-looking statements are based on current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management, and are subject to significant risks and uncertainties. Actual results may differ materially from those expressed or implied by such forward-looking statements due to a variety of factors, including, but not limited to: risks related to clinical trial design, enrollment, timing, interim analyses, and final data outcomes; the possibility that interim results may not be predictive of final trial results; regulatory risks, including the timing and outcome of interactions with the FDA and other regulatory authorities, and the risk that a BLA may not be submitted when anticipated or, if submitted, may not be approved or may require additional data or studies; risks related to safety signals or adverse events that may arise during continued evaluation; the Company’s ability to manufacture sufficient quantities of ANKTIVA and recombinant BCG to support clinical development and potential commercialization; risks associated with product supply, including ongoing BCG shortages; competitive developments; changes in standard-of-care treatment; market acceptance; reimbursement; and intellectual property protection.

More details about these and other risks that may impact ImmunityBio’s business are described under the heading “Risk Factors” in the Company’s Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 23, 2026 and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC’s website at www.sec.gov. ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this press release, except to the extent required by law.

ImmunityBio Contacts:

Investors

Hemanth Ramaprakash, PhD, MBA

ImmunityBio, Inc.

+1 858-746-9289

Hemanth.Ramaprakash@ImmunityBio.com

Media

Sarah Singleton

ImmunityBio, Inc.

+1 415-290-8045

Sarah.Singleton@ImmunityBio.com

FAQ

What new financing did ImmunityBio (IBRX) secure under its amended royalty agreement?

ImmunityBio secured an additional $75.0 million in non-dilutive financing under its existing Revenue Interest Purchase Agreement. This increases total committed capital to $375 million, providing cash to support global commercial expansion and advancement of its broader immunotherapy pipeline, including ANKTIVA®.

How did the revenue interest rates change for ImmunityBio (IBRX) in the amendment?

The amendment raises the tiered revenue interest rate on net sales in the covered territory to 5.625%–12.50%, up from 4.5%–10.0%. These quarterly payments continue until investors receive 195% of cumulative purchaser payments, with rate resets tied to a $375.0 million test in 2029.

What is the 2029 test date condition in ImmunityBio’s (IBRX) royalty agreement?

By the last business day of 2029, if aggregate revenue interest payments reach $375.0 million, the rate drops to 2.8125%. If that threshold is not met, a higher single rate applies going forward, calibrated so past sales would have produced the $375.0 million total.

What debt-to-equity conversion did Nant Capital complete with ImmunityBio (IBRX)?

Nant Capital, affiliated with ImmunityBio’s Executive Chairman, converted $25.0 million of principal under a December 2024 convertible promissory note into 4,606,596 common shares. After this partial note conversion, the remaining principal on the convertible promissory note stands at $480.0 million.

How does the amended RIPA affect ImmunityBio’s (IBRX) obligations and collateral?

ImmunityBio’s obligations under the amended Revenue Interest Purchase Agreement are guaranteed by certain subsidiaries. The company and these guarantors granted a security interest in substantially all their assets, subject to specified exceptions and limitations, to secure payment of revenue interest obligations and related guarantees.

In how many countries is ANKTIVA approved or authorized according to ImmunityBio (IBRX)?

ANKTIVA® plus BCG for BCG-unresponsive non-muscle invasive bladder cancer is now approved or authorized across five regulatory jurisdictions representing about 34 countries. This global footprint was achieved in under two years from initial U.S. FDA approval in 2024, reflecting rapid geographic expansion.

Why does ImmunityBio (IBRX) describe the new Oberland funding as non-dilutive?

The Oberland funding is called non-dilutive because ImmunityBio received $75.0 million in cash in exchange for future revenue-based payments, not by issuing new common equity. Share count impact arises separately from Nant Capital’s $25.0 million debt conversion into 4,606,596 shares.

Filing Exhibits & Attachments

5 documents

Press Releases

• EX-99.1 EX-99.1 19.1 KB

Agreements & Contracts

• EX-10.1 EX-10.1 695.1 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 2.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 16.8 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 10.6 KB